Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:APR NYSE:GKOS NASDAQ:IRTC NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPRApria$37.50$37.45$22.36▼$40.00$1.34BN/A682,285 shsN/AGKOSGlaukos$95.86-0.7%$95.62$77.10▼$163.71$5.54B0.78846,228 shs488,453 shsIRTCiRhythm Technologies$169.98-0.9%$150.26$55.92▼$172.59$5.51B1.41545,079 shs193,610 shsNUVLNuvalent$76.58+0.7%$78.54$55.53▼$113.51$5.48B1.3433,328 shs418,360 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPRApria0.00%0.00%0.00%0.00%0.00%GKOSGlaukos-0.71%+1.75%+1.96%+1.62%-29.20%IRTCiRhythm Technologies-0.87%+0.51%+21.34%+20.24%+147.93%NUVLNuvalent+0.74%+0.66%-3.72%+4.01%-9.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPRApriaN/AN/AN/AN/AN/AN/AN/AN/AGKOSGlaukos4.6914 of 5 stars4.44.00.04.42.71.70.6IRTCiRhythm Technologies1.2983 of 5 stars2.51.00.00.03.40.80.6NUVLNuvalent3.3958 of 5 stars4.51.00.00.03.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPRApria 0.00N/AN/AN/AGKOSGlaukos 2.79Moderate Buy$127.4232.92% UpsideIRTCiRhythm Technologies 3.00Buy$163.82-3.63% DownsideNUVLNuvalent 3.09Buy$120.8057.74% UpsideCurrent Analyst Ratings BreakdownLatest APR, NUVL, IRTC, and GKOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025IRTCiRhythm TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$180.00 ➝ $193.008/21/2025IRTCiRhythm TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$167.00 ➝ $183.008/20/2025IRTCiRhythm TechnologiesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$200.008/19/2025NUVLNuvalentPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$112.008/15/2025GKOSGlaukosZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/1/2025IRTCiRhythm TechnologiesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/1/2025IRTCiRhythm TechnologiesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$145.00 ➝ $190.008/1/2025IRTCiRhythm TechnologiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$139.00 ➝ $170.008/1/2025IRTCiRhythm TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $180.008/1/2025IRTCiRhythm TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$151.00 ➝ $180.007/31/2025GKOSGlaukosMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$130.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPRApria$1.15B1.17$5.27 per share7.12$1.12 per share33.48GKOSGlaukos$383.48M14.34N/AN/A$13.34 per share7.19IRTCiRhythm Technologies$591.84M9.23N/AN/A$3.23 per share52.63NUVLNuvalentN/AN/AN/AN/A$13.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPRApria$64.88MN/A0.0020.49N/A5.66%586.18%9.23%N/AGKOSGlaukos-$146.37M-$1.65N/AN/AN/A-21.43%-8.59%-6.61%11/3/2025 (Estimated)IRTCiRhythm Technologies-$113.29M-$2.93N/AN/AN/A-14.06%-90.03%-8.52%10/29/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)Latest APR, NUVL, IRTC, and GKOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A7/31/2025Q2 2025IRTCiRhythm Technologies-$0.53-$0.32+$0.21-$0.44$173.94 million$186.69 million7/30/2025Q2 2025GKOSGlaukos-$0.26-$0.24+$0.02-$0.34$115.49 million$124.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPRApriaN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPRApria8.581.091.06GKOSGlaukos0.095.514.69IRTCiRhythm Technologies6.255.024.88NUVLNuvalentN/A13.5713.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPRApriaN/AGKOSGlaukos99.04%IRTCiRhythm TechnologiesN/ANUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipAPRApriaN/AGKOSGlaukos5.80%IRTCiRhythm Technologies1.10%NUVLNuvalent10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPRApria6,08035.65 millionN/ANot OptionableGKOSGlaukos78057.35 million54.02 millionOptionableIRTCiRhythm Technologies2,00032.13 million31.78 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableAPR, NUVL, IRTC, and GKOS HeadlinesRecent News About These CompaniesNuvalent, Inc. $NUVL Holdings Raised by Affinity Asset Advisors LLCAugust 28 at 9:02 AM | marketbeat.comNuvalent to Participate in the Cantor Global Healthcare Conference 2025August 28 at 6:30 AM | prnewswire.comPrice T Rowe Associates Inc. MD Raises Stock Position in Nuvalent, Inc. $NUVLAugust 28 at 4:52 AM | marketbeat.comNuveen LLC Buys Shares of 83,976 Nuvalent, Inc. $NUVLAugust 28 at 3:36 AM | marketbeat.comT. Rowe Price Investment Management Inc. Makes New $31.97 Million Investment in Nuvalent, Inc. $NUVLAugust 26, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by American Century Companies Inc.August 26, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by Wellington Management Group LLPAugust 24, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Deutsche Bank AGAugust 24, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Charles Schwab Investment Management Inc.August 24, 2025 | marketbeat.comCandriam S.C.A. Sells 13,966 Shares of Nuvalent, Inc. $NUVLAugust 23, 2025 | marketbeat.comAberdeen Group plc Acquires 19,987 Shares of Nuvalent, Inc. $NUVLAugust 23, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by Russell Investments Group Ltd.August 22, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) CEO Sells $2,036,340.00 in StockAugust 21, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) Now Covered by Piper SandlerAugust 21, 2025 | marketbeat.comInsider Selling: Nuvalent (NASDAQ:NUVL) CEO Sells 27,000 Shares of StockAugust 20, 2025 | insidertrades.comPiper Sandler Initiates Coverage on Nuvalent (NASDAQ:NUVL)August 20, 2025 | americanbankingnews.comPiper Sandler Initiates Coverage of Nuvalent (NUVL) with Overweight RecommendationAugust 19, 2025 | msn.comNuvalent initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comVanguard Group Inc. Decreases Holdings in Nuvalent, Inc. $NUVLAugust 19, 2025 | marketbeat.comLord Abbett & CO. LLC Sells 112,621 Shares of Nuvalent, Inc. (NASDAQ:NUVL)August 18, 2025 | marketbeat.comCitigroup Inc. Purchases 112,519 Shares of Nuvalent, Inc. (NASDAQ:NUVL)August 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPR, NUVL, IRTC, and GKOS Company DescriptionsApria NYSE:APRApria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. Apria, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana. As of March 29, 2022, Apria, Inc. operates as a subsidiary of Byram Healthcare Centers, Inc.Glaukos NYSE:GKOS$95.86 -0.70 (-0.73%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$95.80 -0.06 (-0.06%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.iRhythm Technologies NASDAQ:IRTC$169.98 -1.49 (-0.87%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$168.50 -1.48 (-0.87%) As of 08/29/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Nuvalent NASDAQ:NUVL$76.58 +0.56 (+0.74%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$76.60 +0.02 (+0.02%) As of 08/29/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
